Accreditation Information

Direct Accreditation:

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Boston University School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives

Neurol Clin. 2020 May;38(2):469-480. doi: 10.1016/j.ncl.2020.01.011. Epub 2020 Mar 9. PMID: 32279721.

Target Audience

Neurologists, neurosurgeons, neuroradiologists, pediatric neurologists, psychiatrists, basic scientists and health care providers in those fields.  

Faculty Disclosure

Faculty, Planning Committee and CME Administrator disclosure statement:

Kathrin LaFaver, Speaker, has no relevant financial relationships to disclose.

David Greer, Course Director, has no relevant financial relationships to disclose.

Marie Saint-Hilaire, Co-Course Director, has no relevant financial relationships to disclose.

Sunali Shah, Planning Committee, has no relevant financial relationships to disclose.

Jonathan Dashkoff, Planning Committee, has no relevant financial relationships to disclose.

Sakina Flint, Program Manager, has no relevant financial relationships to disclose.

Faculty disclosure of off-label use:

Faculty member does not plan on discussing unlabeled/investigational uses of a commercial product.

Faculty disclosure policy:

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.